New Fees Hit OTC Drug Makers for 2026
Published Date: 3/18/2026
Notice
Summary
Starting October 1, 2025, companies that make or submit requests for over-the-counter (OTC) drug products will pay new facility fees for fiscal year 2026. These fees help the FDA keep OTC drugs safe and effective. If you own or run an OTC drug facility, get ready for these updated charges that last through September 30, 2026.
Analyzed Economic Effects
5 provisions identified: 0 benefits, 3 costs, 2 mixed.
FY2026 OTC Facility Fee Amounts
If you own an OTC monograph drug manufacturing facility (MDF), you will be charged a facility fee of $19,188 for the period October 1, 2025 through September 30, 2026. If your facility is a contract manufacturing organization (CMO), the fee for FY2026 is $12,792 (two-thirds of the MDF fee).
Who Is Assessed Fees (Fee-Liability Window)
Facilities identified as OTC monograph drug facilities during the fee-liable period from January 1, 2025 through December 31, 2025 will be assessed an FY2026 facility fee. A full fee is assessed for each MDF and a reduced fee (two-thirds) is assessed for each CMO facility.
Which Facilities Are Exempt or Excluded
Facilities that ceased OTC monograph drug activities and updated their FDA registration to that effect before January 1, 2025 are exempt from FY2026 facility fees. Also excluded from being OTC monograph drug facilities (and thus not assessed fees) are facilities whose only activities are manufacture of active pharmaceutical ingredient (API), production of clinical research supplies, testing, or placement of outer overpackaging on already-final packaged products. By contrast, relabelers and repackagers are treated as fee-subject OTC monograph drug facilities.
Payment Timing, Methods, and Consequences
FY2026 facility fees are due on June 1, 2026 (the later of June 1 or the first business day after an appropriations Act) and invoices will be issued in April 2026. Payments must be in U.S. currency drawn on a U.S. bank and are accepted online via Pay.gov (ACH/eCheck) or credit card (credit card payments allowed only for balances under $25,000); full payments only (no partial online payments). Unpaid fees will be treated as claims of the U.S. Government and referred to collection.
Change in Fee Due Date Starting FY2027
OMUFA II transitions facility fee due dates so that, starting in FY2027, facility fees will be due the first business day in October; for FY2027 specifically, fees will be due in two equal installments on the first business day of October and the first business day of February. This changes the prior timing when fees were due in the third fiscal quarter (June).
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-06478 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY
The FDA has officially set the review period for VYLOY, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind VYLOY, giving them a chance to extend their patent protection and potentially boost profits. If anyone thinks the dates are wrong or wants to challenge the company’s review speed, they must act by June 2 or September 30, 2026.
2026-06481 — Determination of Regulatory Review Period for Purposes of Patent Extension; HYMPAVZI
The FDA has set the official review period for HYMPAVZI, a new human biological product, so its patent holder can apply for extra patent time. This affects the company behind HYMPAVZI and anyone interested in patent extensions. If you think the dates are wrong or want to challenge the company’s diligence, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06480 — Determination of Regulatory Review Period for Purposes of Patent Extension; EMRELIS
The FDA has officially set the review period for EMRELIS, a medicine patent, so the patent owner can apply for extra protection time. If anyone thinks the dates are wrong, they have until June 2, 2026, to speak up. Also, people can challenge whether the patent owner was diligent during the review by September 30, 2026. This affects patent holders and could impact how long they keep exclusive rights to their product.
2026-06479 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENFLONSIA
The FDA has set the official review period for ENFLONSIA, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind ENFLONSIA and anyone interested in patent rules. If you think the dates are wrong or want to challenge the company’s review speed, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06477 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENCELTO
The FDA has officially set the review period for ENCELTO, a medicine patent, so the company can apply to extend its patent protection. This affects the drug maker by potentially giving them more time to exclusively sell ENCELTO, which can mean more money. If anyone thinks the dates are wrong or the company wasn’t diligent, they have until June 2 or September 30, 2026, to speak up.
2026-06483 — Determination of Regulatory Review Period for Purposes of Patent Extension; INJECTAFER
The FDA has officially set the review period for INJECTAFER, a drug patent up for extension. This means the company can apply to extend their patent protection, potentially keeping their exclusive rights longer and impacting competition and pricing. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by June 2 or September 30, 2026.
Previous / Next Documents
Previous: 2026-05275 — Physicochemical and Structural (Q3) Characterization of Topical Drug Products Submitted in Abbreviated New Drug Applications; Guidance for Industry, Availability
The FDA just released new rules to help companies making generic skin creams and gels prove their products work the same as brand-name ones. If you submit these drug applications, you’ll need to show detailed info about your product’s makeup and structure to get approval. This update starts now and aims to speed up safe, affordable generics without extra costs.
Next: 2026-05277 — Hazardous Materials: Notice of Applications for New Special Permits
The Department of Transportation just announced new requests for special permits to safely move hazardous materials by trucks, trains, ships, and planes. Companies and anyone involved in shipping dangerous goods should check these applications and send comments by April 17, 2026. These permits could change how some hazardous materials are handled, possibly speeding up shipments or adding new safety rules without extra costs.
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in